{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"22.0","value":"14.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest objective status is first noted to be either a CR or PR to the earliest date progression is documented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"All Patients (Everolimus and Lenalidomide)"}],"paramType":"MEDIAN","populationDescription":"All eligible patients that began study treatment and evaluated as a CR, PR or MR during treatment were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Duration of Response for All Eligible Patients","type":"SECONDARY","unitOfMeasure":"months"}